We present the study design for ‘HER-SAFE’, the first randomised controlled trial of HFT withdrawal in patients with recovered CTRCD—specifically breast cancer survivors who experienced HER2-targeted therapy cardiotoxicity. This evidence concerns the gene ERBB2 and breast carcinoma.